Literature DB >> 33217679

Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.

Stefano Restaino1, Lucia Tortorella1, Giorgia Dinoi2, Gian-Franco Zannoni3, Alessandro Baroni2, Ilaria Capasso2, Ettore Distefano2, Giulio Sozzi4, Vito Chiantera4, Giovanni Scambia5, Francesco Fanfani6.   

Abstract

OBJECTIVES: The interpretation of lymph-vascular space invasion (LVSI) is usually qualitative, as presence or absence. The aim of this study is to investigate the prognostic role of LVSI in patients affected by endometrial cancer, when evaluated with a semiquantitative analysis.
METHODS: This retrospective multicentre study enrolled patients who received a histologically confirmed diagnosis of endometrial cancer. The assessment of LVSI was semiquantitative in accordance with the three-tiered scoring system (absent, focal and diffuse).
RESULTS: Among 1258 patients with surgical-stage endometrial cancer, LVSI has been found in 32.8% of cases (n = 412), whose 12.7% (n = 160) were focal, and 20% (n = 252) diffuse. The rate of lymph node metastasis increased from the 5% in patients with no LVSI to 15% in patients with focal LVSI and 33% in those with diffuse LVSI (p < 0.001). Distant recurrences were more frequent in patients with diffuse LVSI than in focal or no LVSI (24.9% versus 14.7% and 6.6%, respectively, p < 0.001). Diffuse LVSI was found to significantly increase the risk of distant metastasis (adjusted odds ratio (A OR) 2.57, p < 0.001). Adjuvant radiation were associated with improved overall survival (OS) and disease-free survival (DFS) in patients with diffuse LVSI.
CONCLUSION: The presence of diffuse LVSI is an independent risk factor for both lymph node metastasis and distant recurrence in endometrial cancer patients, and it is associated with a significantly decreased OS and DFS. Adjuvant radiation improved survival regardless of grading, histotype and lymph nodal metastasis in women with diffuse LVSI.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; LVSI; Lymph-vascular space invasion; Recurrence

Mesh:

Year:  2020        PMID: 33217679     DOI: 10.1016/j.ejca.2020.10.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.

Authors:  Su-Ding Zhu; Jing Zhang; Xiao-Jing Liu; Jun-Hui Zhang; Bing Wei; Wen-Yan Wang; Yi-Jun Fan; Dan Li; Yun-Xia Cao; Lei Zhan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  Assessing Metabolic Risk Factors for LVSI in Endometrial Cancer: A Cross-Sectional Study.

Authors:  Qiaoyan Lin; Yongwei Lu; Rong Lu; Yujuan Chen; Linghua Wang; Jianping Lu; Xianren Ye
Journal:  Ther Clin Risk Manag       Date:  2022-08-09       Impact factor: 2.755

Review 3.  Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature.

Authors:  Stefano Restaino; Giorgia Dinoi; Eleonora La Fera; Benedetta Gui; Serena Cappuccio; Maura Campitelli; Giuseppe Vizzielli; Giovanni Scambia; Francesco Fanfani
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.